Lilly, Merck Deals Mark Start Of New Era For Indian Drug Firms – PharmAsia News Spotlight
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A new patent law to protect intellectual property and in-depth experience in clinical trials and manufacturing has helped Indian drug firms such as Piramal Healthcare become equal partners with multinational counterparts in sharing risks, costs and profits, according to a senior company executive